Retinal function and morphology in the rabbit eye after intravitreal injection of the TNF alpha inhibitor adalimumab

Current Eye Research

Volumn 39, Issue 11, 2014, Pages 1106-1116

  Myers, Anna Cardiakidis ^a   Ghosh, Fredrik ^a   Andreásson, Sten ^a   Ponjavic, Vesna ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Adalimumab; Drug toxicity; Electrophysiology; Histopathology; Intravitreal injection; Rabbit retina; Retinal function; Tumor necrosis factor Alpha inhibitor

Indexed keywords

ADALIMUMAB; BALANCED SALT SOLUTION; CALBINDIN; GLIAL FIBRILLARY ACIDIC PROTEIN; PARVALBUMIN; PROTEIN KINASE C ALPHA; RHODOPSIN; ANTIINFLAMMATORY AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; ELECTRORETINOGRAPHY; FULL FIELD ELECTRORETINOGRAPHY; IMMUNOHISTOCHEMISTRY; MUELLER CELL; NONHUMAN; RABBIT; RETINA; RETINA AMACRINE CELL; RETINA BIPOLAR GANGLION CELL; RETINA CONE; RETINA HORIZONTAL NERVE CELL; RETINA ROD; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; FLUORESCENT ANTIBODY TECHNIQUE; INTRAVITREAL DRUG ADMINISTRATION; METABOLISM; PATHOPHYSIOLOGY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; CALBINDINS; ELECTRORETINOGRAPHY; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GLIAL FIBRILLARY ACIDIC PROTEIN; INTRAVITREAL INJECTIONS; PARVALBUMINS; PROTEIN KINASE C-ALPHA; RABBITS; RETINA; RHODOPSIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84911970080     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.3109/02713683.2014.898309     Document Type: Article

References (58)

1. Rifkin LM, Birnbaum AD, Goldstein DA. TNF inhibitionfor ophthalmic indications:current status and outlook. Bio Drugs 2013;27:347-357.
2. Khera TK, Dick AD, Nicholson LB. Mechanisms of TNFa regulation in uveitis: focus on RNA-binding proteins. Prog Retin Eye Res 2011;30:610-621.
3. Mirshahi A, Hoehn R, Lorenz K, Kramann C, Baatz H. Anti-tumor necrosis factor alpha for retinal diseases:current knowledge and future concepts. J Ophthalmic Vis Res 2012;7:39-44.
4. Dick AD, Forrester JV, Liversidge J, Cope AP. The role of tumour necrosisi factor(TNF-A) in experimental autoimmune uveoretinitis (EAU). Prog Retin Eye Res 2004;23: 617-637.
5. Malaviya AP, Ostör AJ. Rheumatoid arthritis and the era of biologic therapy. Inflammopharmacol 2012;20:59-69.
6. Rosenbaum JT, Howes EL, Rubin R, Samples JR. Ocular inflammatory effects of intravitreally-injected tumour necrosis factor. Am J Pathol 1988;133:47-53.
7. Mushtaq B, Saeed T, Situnayake RD, Murray PI. Adalimumab for sight-threatening uveitis in Behçet's disease. Eye (Lond) 2007;21:824-825.
8. Galor A, Perez VL, Hammel JP, Lowder CY. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology 2006;113: 2317-2323.
9. Erckens RJ, Mostard RL, Wijnen PA, Schouten JS, Drent M. Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis. Graefes Arch Clin Exp Ophthalmol 2012;250:713-720.
10. Accorinti M, Pirraglia MP, Paroli MP, Priori R, Conti F, Pivetti-Pezzi P. Infliximab Treatment for ocular and extraocular Behçet's disease. Jpn J Ophthalmol 2007;51: 191-196.
11. Biester S, Deuter C, Michels H, Haefner R, Kuemmerle-Deschner J, Doycheva D, Zierhut M. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol 2007;91: 319-324.
12. Bawazeer A, Raffa LH, Nizamuddin SH. Clinical experience with adalimumab in the treatment of ocular Behçet disease. Ocul Immunol Inflamm 2010;18:226-232.
13. van Laar JA, Missotten T, van Daele PL, Jamnitski A, Baarsma GS, van Hagen PM. Adalimumab: a new modality for Behçet's disease? Ann Rheum Dis 2007;66:565-566.
14. Joseph A, Raj D, Dua HS, Powell PT, Lanyon PC, Powell RJ. Infliximab in the treatment of refractory posterior uveitis. Ophthalmology 2003;110:1449-1453.
15. Foeldvari I, Nielsen S, Kümmerle-Deschner J, Espada G, Horneff G, Bica B, et al. Tumor necrosis factor alpha blocker in treatment of juvenile idiopathic arthritis associated uveitis refractory to second line agents: results of a multinational survey. J Rheumatol 2007;34:1146-1150.
16. Limb GA, Chignell AH, Green W, LeRoy F, Dumonde DC. Distribution of TNFa and vascular adhesion molecules in fibrocellular membranes of proliferative diabetic retinopathy. Br J Opthlamol 1996;80:168-173.
17. El Ghrably IA, Dua HS, Orr GV, Fischer D, Tighe PJ. Detection of cytokine mRNA production in infiltrating cells in proliferative vitreoretinopathy using reverse transcription polymerase chain reaction. Br J Ophthalmol 1999; 83:1296-1299.
18. Limb GA, Earley O, Jones SE, LeRoy F, Chignell AH, Dumonde DC. Expression of mRNA coding for TNF alpha, IL-1 beta and IL-6 by cells infiltrating retinal membranes. Graefes Arch Clin Exp Ophthalmol 1994;232: 646-651.
19. Limb GA, Hollifield RD,Webster L, Charteris DG, Chignell AH. Soluble TNF receptors in vitreoretinal proliferative disease. Invest Ophthalmol Vis Sci 2001;42:1586-1591.
20. Tezel G, Li LY, Patil RV, Wax MB. TNF-Alpha and TNF-Alpha receptor-1 in the retina of normal and glaucomatous eyes. Invest Ophthalmol Vis Sci 2001;42: 1787-1794.
21. Berger S, Savitz SI, Nijhawan S, Singh M, David J, Rosenbaum PS, Rosenbaum DM. Deleterious role of TNF-A in retinal ischemia-reperfusioin injury. Invest Opthalmol Vis Sci 2008;49:3605-3610.
22. Gesslein B, Ha°kansson G, Gustavsson L, Ekström P, Malmsjö M. Tumor necrosis factor and its receptors in the neuroretina and retinal vasculature after ischemiareperfusion injury in the pig retina. Mol Vis 2010;16: 2317-2327.
23. Semkova I, Muether PS, Kuebbeler M, Meyer KL, Kociok N, Joussen AM. Recruitment of blood-derived inflammatory cells mediated via tumor necrosis factor (TNF)-A receptor 1b exacerbates CNV. Invest Ophthalmol Vis Sci 2011;52:6101-6108.
24. Jasielska M, Semkova I, Shi X, Schmidt K, Karagiannis D, Kokkinou D, Mackiewicz J, et al. Differential role of tumor necrosis factor (TNF) alphareceptors in the development of choroidal neovascularization. Invest Ophthalmol Vis Sci 2010;51:3874-3883.
25. Lichtlen PD, Lam T, Nork M, Streit T, Urech DM. Relative contribution of VEGF and TNF-Alpha in the cynomolgus laser-induced CNV model:comparing efficacy of bevacizumab, adalimumab and ESBA105. Invest Ophthalmol Vis Sci 2010;51:4738-4735.
26. Yoshida S, Yoshida A, Ishibashi T. Induction of IL-8, MCP-1, and bFGF by TNF-A in retinal glial cells: implications for retinal neovascularization during post-ischemic inflammation. Graefe's Arch Clin Exp Ophthalmol 2004; 242:409-413.
27. Olsson JL, Courtney RJ, Mandava N. Intravitreal infliximab and choroidal neovascularization in an animal model. Arch Ophthalmol 2007;125:1221-1224.
28. Martel J N, Esterberg E, Nagpal A, Acharya NR. Infliximab and adalimumab for uveitis. Ocul Immunol Inflamm 2012; 20:18-20.
29. Kaymakcalan Z, Sakorafas P, Bose S, Scesney S, Xiong L, Hanzatian Karaglu D, et al. Comparisons of affinities, avidities and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor. Clin Immunol 2008;131: 308-316.
30. Giganti M, Beer PM, Lemanski N. Adverse events after intravitreal infliximab (Remicade). Retina 2010;30:71-80.
31. Thalayasingam N, Isaacs JB. Anti-TNF therapy. Best Pract Res Clin Rheumatol 2011;25:549-567.
32. Wu L, Arevalo F, Hernandez-Bogantes E, Regatieri C, Rocca JA, Farah ME. Intravitreal tumor necrosis factor alpha inhibitors for neovascular age related degeneration suboptimally responsive to anti-vascular endotheial growth factor agents: a pilot study from the pan-American collaborative retina study group. J Ocul Pharmacol Ther 2013;29:366-371.
33. Lim LL, Frauenfelder FW, Rosenbaum JT. Do tumor necrosis inhibitors cause uveitis, a registry-based study. Arthritis Rheum 2007;56:3248-3252.
34. Mansour AM. Adalimumab in the therapy of uveitis in childhood. Brit J Ophthalmol 2007;91:274-276.
35. Reddy AR, Backhouse OC. Does etanercept induce uveitis? Brit J Ophthalmol 2002;87:1-11.
36. Gjörloff K, Andreásson S, Ehinger B. Standardized fullfield electroretinography in rabbits. Doc Ophthalmol 2004; 109:163-168.
37. Marmor M, Fulton AB, Holder GE, Miyake Y, Brigell M, Bach M. ISCEV standard for full-field clinical electroretinography (2008 update). Doc Ophthalmol 2008;118:69-77.
38. Koistinaho J, Sagar SM. Localization of protein kinase C subspecies in the rabbit retina. Neurosci Lett 1994;177: 15-18.
39. Wood JPM, McCord RJ, Osborne NN. Retinal protein kinase C. Neurochem Int 1997;30:119-136.
40. Lewis P, Fisher SK. Up regulation of glial fibrillary acidic protein in response to retinal injury: its potential role in glial remodeling and a comparison to vimentin expression. Int Rev Cytol 2003;230:263-289.
41. Casini G, Rickman DW, Brecha NC. AII amacrine cell population in the rabbit retina: identification by parvalbumin immunoreactivity. J Comp Neurol 1995;356:132-142.
42. MacKenzie D, Arendt A, Hargrave P, McDowell JH, Molday RS. Localization of binding sites for carboxyl terminal specific antirhodopsin monoclonal antibodies using synthetic peptides. Biochemistry 1984;18:6544-6549.
43. Massey SC, Mills SL. A calbindin-immunoreactive cone bipolar cell type in the rabbit retina. J Comp Neurol 1996; 366:15-33.
44. Blanks J, Johnson LV. Specific binding of peanut lectin to a class of retinal photoreceptor cells. Invest Ophthalmol Vis Sci 1982;25:546-557.
45. Kjellström U, Bruun A, Ghosh F, Andreásson S, Ponjavic V. Dose-related changes in retinal function and PKC-Alpha expression in rabbits on vigabatrin medication. Graefe's Arch Clin Exp Ophthalmol 2009;247:1057-1067.
46. Perlman I. Testing retinal toxicity of drugs in animals using electrophysiological and morpholpgical techniques. Doc Opthalmol 2009;118:3-28.
47. Peyman GA, Conway MD, Fiscella R. Interaction of intravitreal combination drugs and the effect on the targeted site. J Ocul Pharmacol Ther 2009;25:387-394.
48. Ghasemi Falavarjani K, Ngyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye 2013;27:787-794.
49. Tsilimbaris M, Diakonis VF, Naoumidi I, Charisis S, Kritikos I, Chatzithanasis G, et al. Evaluation of potential retinal toxicity of adalimumab (Humira). Graefes Arch Clin Exp Ophthalmol 2009;247:1119-1125.
50. Manzano PR, Peyman GA, Carvounis PE, Damico FM, Aguiar RG, Ioshimoto GL, et al. Toxicity of high-dose intravitreal adalimumab (humira) in the rabbit. J Ocul Pharmacol Ther 2011;27:327-331.
51. Manzano RP, Peyman GA, Carvounis PE, Kivilcim M, Khan P, Chevez-Barrios P, et al. Ocular toxicity of intravitreous adalimumab (Humira) in the rabbit. Graefes Arch Clin Exp Ophthalmol 2008;246:907-911.
52. Theodossiadis PG, Liarakos VS, Sfikakis PP, Vergados IA, Theodossiadis GP. Intravitreal administration of the antitumor necrosis factor agent infliximab for neovascular agerelated macular degeneration. Am J Ophthalmol 2009;147: 825-830.
53. Androudi S, Tsironi E, Kalogeropoulos C, Theodoridou A, Brazitikos P. Intravitreal adalimumab for refractory uveitisrelated macular edema. Ophthalmology 2010;117: 1612-1616.
54. Farvardin M, Afarid M, Sharzad S. Long-term effects of intravitreal infliximab for treatment of sight-threatening chronic noninfectious uveitis. J Ocul Pharmacol Ther 2012; 28:628-631.
55. Nakasawa T, Kayama M, Ryu M, Kunikata H, Watanabe R, Yasuda M, et al. Tumor necrosis factor-A mediates photoreceptor death in a rodent model of retinal detachment. Invest Ophthalmol Vis Sci 2011;52:1384-1391.
56. Nakasawa T, Matsurbata A, Noda K, Hisatomi T, She H, Skondra D, et al. Characterization of cytokine response to retinal detachment in rats. Mol Vis 2006;12:867-878.
57. De Oliveira Dias JR, Büchele Rodrigues E, Maia M, Magalhaes O, Marcondes Penha F, Farah ME. Cytokines in neovascular age-related macular degeneration: fundamentals of targeted combination therapy. Br J Ophthalmol 2011;95:1631-1637.
58. Giraudo E, Primo L, Audero E, Gerber HP, Koolwijk P, Soker S, et al. Tumor necrosis factor-Alpha regulates expression of endothelial growth factor receptor-2 and its co-receptor neuropilin-1 in human vascular endothelial cells. J Biol Chem 1998;273:22128-22135.